A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy.

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 07 May 2018

At a glance

  • Drugs Abiraterone acetate (Primary) ; Prednisone
  • Indications Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Cougar Biotechnology; Janssen Research & Development
  • Most Recent Events

    • 07 May 2018 Results of a post-hoc analysis of COU-AA-301 and IMMC-38 trials (n=511) assessing biomarkers of disease progression in mCRPC patients, published in the Annals of Oncology
    • 24 Mar 2018 Results of joint model analysis characterizing the relationship between PSA kinetics and rPFS (COUAA301 and COUAA302) presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 11 Dec 2017 Results of post hoc analysis of COU-AA-301 and COU-AA-302 assessing relationships between changes in PRO measures and clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC), were published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top